94.65 USD
+0.64 (+0.68%)
94.65 USD
0 (0%)
Overall AZN gets a fundamental rating of 6 out of 10. We evaluated AZN against 191 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are some minor concerns on its financial health. AZN is not valued too expensively and it also shows a decent growth rate. Finally AZN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
AZN had positive earnings in the past year.
In the past year AZN had a positive cash flow from operations.
Each year in the past 5 years AZN has been profitable.
Each year in the past 5 years AZN had a positive operating cash flow.
1.2 Ratios
AZN's Return On Assets of 8.21% is amongst the best of the industry. AZN outperforms 89.53% of its industry peers.
With an excellent Return On Equity value of 20.48%, AZN belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
The Return On Invested Capital of AZN (14.42%) is better than 93.72% of its industry peers.
AZN had an Average Return On Invested Capital over the past 3 years of 11.62%. This is in line with the industry average of 12.85%.
The 3 year average ROIC (11.62%) for AZN is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
AZN has a better Profit Margin (16.17%) than 88.48% of its industry peers.
AZN's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 24.34%, AZN belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
In the last couple of years the Operating Margin of AZN has grown nicely.
With an excellent Gross Margin value of 81.90%, AZN belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, AZN has more shares outstanding
Compared to 1 year ago, AZN has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.55 indicates that AZN is not in any danger for bankruptcy at the moment.
The Altman-Z score of AZN (3.55) is better than 66.49% of its industry peers.
AZN has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as AZN would need 3.41 years to pay back of all of its debts.
The Debt to FCF ratio of AZN (3.41) is better than 86.91% of its industry peers.
AZN has a Debt/Equity ratio of 0.61. This is a neutral value indicating AZN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.61, AZN is doing worse than 68.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.55 |
ROIC/WACC1.64
WACC8.82%
2.3 Liquidity
A Current Ratio of 0.88 indicates that AZN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.88, AZN is doing worse than 87.43% of the companies in the same industry.
AZN has a Quick Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.69, AZN is not doing good in the industry: 86.39% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
AZN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.45% on average per year.
Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 7.17% on average per year.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.58, which indicates a rather expensive current valuation of AZN.
79.58% of the companies in the same industry are more expensive than AZN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.19, AZN is valued a bit cheaper.
AZN is valuated rather expensively with a Price/Forward Earnings ratio of 18.08.
Based on the Price/Forward Earnings ratio, AZN is valued a bit cheaper than 78.01% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AZN to the average of the S&P500 Index (23.88), we can say AZN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.58 | ||
| Fwd PE | 18.08 |
4.2 Price Multiples
81.68% of the companies in the same industry are more expensive than AZN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AZN is valued cheaply inside the industry as 80.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.67 | ||
| EV/EBITDA | 15.17 |
4.3 Compensation for Growth
AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AZN has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.20% in the coming years.
PEG (NY)1.72
PEG (5Y)1.11
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.77%, AZN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 0.42, AZN pays a better dividend. On top of this AZN pays more dividend than 92.15% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.94, AZN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.77% |
5.2 History
The dividend of AZN has a limited annual growth rate of 1.40%.
AZN has paid a dividend for at least 10 years, which is a reliable track record.
AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
52.89% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
94.65
+0.64 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners49.17%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap293.47B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target97.35 (2.85%)
Short Float %0.28%
Short Ratio1.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.77% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)4.58%
PT rev (3m)7.67%
EPS NQ rev (1m)1.34%
EPS NQ rev (3m)-0.6%
EPS NY rev (1m)-1.9%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.58 | ||
| Fwd PE | 18.08 | ||
| P/S | 5.05 | ||
| P/FCF | 30.67 | ||
| P/OCF | 19.38 | ||
| P/B | 6.4 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.17 |
EPS(TTM)4.6
EY4.86%
EPS(NY)5.24
Fwd EY5.53%
FCF(TTM)3.09
FCFY3.26%
OCF(TTM)4.88
OCFY5.16%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.72
PEG (5Y)1.11
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.55 |
F-Score7
WACC8.82%
ROIC/WACC1.64
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.58 and the Price/Book (PB) ratio is 6.4.
What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 11.95% in the next year.